NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
Clinical Trials
15 trialsNCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT03311750 2021-06-07
A-REPEAT
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT01057017 2020-02-17
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Phase 2 Terminated
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT01916109 2016-02-12
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01296035 2015-08-25
PanGem
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT01374789 2015-06-03
PURO
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Terminated
NCT01038037 2014-12-04
Lung-TRIO
Vejle Hospital
Phase 2 Terminated
NCT01305772 2014-08-29
TOP0901
Duke University
Phase 2 Terminated
NCT00613730 2014-01-06
APPRISE 1
Amgen
Phase 2 Terminated
NCT01017653 2013-09-04
Panitumumab and Irinotecan for Malignant Gliomas
Duke University
Phase 2 Terminated
NCT00950820 2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01262183 2012-05-11
PANORAMIC
Radboud University Medical Center
Phase 2 Terminated